AgomAb Therapeutics (NASDAQ:AGMB) Trading 9.6% Higher – Still a Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price was up 9.6% during mid-day trading on Monday . The company traded as high as $15.20 and last traded at $15.13. 40,410 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 141,930 shares. The stock had previously closed at $13.81.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AGMB. JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price target for the company. Leerink Partners began coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price for the company. Morgan Stanley began coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 price target on the stock. Zacks Research upgraded shares of AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Finally, HC Wainwright initiated coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.75.

AgomAb Therapeutics Stock Performance

The company has a fifty day simple moving average of $11.19.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.